adeno-associated virus

adeno-associated virus. A small, non-enveloped virus belonging to the genus Dependoparvovirus within the family Parvoviridae. It is characterized by its inability to replicate autonomously, requiring co-infection with a helper virus, such as adenovirus or herpesvirus, for a productive infection. Its simple structure, non-pathogenic nature in humans, and ability to establish long-term gene expression in non-dividing cells have made it a leading viral vector for gene therapy and genetic research.

Structure and genome

The virion possesses a simple, rugged icosahedral capsid approximately 26 nanometers in diameter, composed of three viral proteins: VP1, VP2, and VP3. This protein shell encloses a linear, single-stranded DNA genome of about 4.7 kilobases. The genome is flanked by two inverted terminal repeat (ITR) sequences, which are the only cis-acting elements required for genome replication and packaging. The internal genome contains two main open reading frames: *rep*, which encodes non-structural proteins essential for replication, and *cap*, which encodes the structural capsid proteins. The genomic organization is highly conserved across different serotypes.

Replication and life cycle

Replication is entirely dependent on the presence of a helper virus, such as adenovirus, which provides essential functions to bypass cellular latency. In the absence of a helper, the viral genome can integrate site-specifically into a region on human chromosome 19 known as AAVS1, establishing a latent infection. Upon superinfection with a helper virus, the integrated genome is rescued, leading to lytic replication. The Rep proteins initiate DNA replication via a rolling hairpin mechanism, and newly synthesized genomes are packaged into pre-formed capsids within the cell nucleus. The life cycle culminates in cell lysis and release of progeny virions, facilitated by the co-infecting helper virus.

Serotypes and tissue tropism

Over a dozen distinct natural serotypes and hundreds of engineered capsid variants have been identified, each with unique tissue tropism determined by differences in capsid protein sequences. For instance, AAV2 efficiently transduces skeletal muscle and neurons, while AAV8 shows high affinity for liver hepatocytes. AAV9 and engineered variants like AAV-PHP.eB can cross the blood-brain barrier, enabling efficient central nervous system transduction. This diversity allows researchers to select or engineer vectors for targeted delivery to specific organs, such as the retina, heart, or pancreas, for therapeutic applications.

Applications in gene therapy

It has become the vector of choice for numerous clinical trials and approved therapies due to its safety profile and long-term transgene expression. The first FDA-approved gene therapy product in the United States, Luxturna (voretigene neparvovec), uses an AAV2 vector to treat an inherited form of retinal dystrophy caused by mutations in the RPE65 gene. Similarly, Zolgensma (onasemnogene abeparvovec), an AAV9-based therapy, is used to treat spinal muscular atrophy. Ongoing research at institutions like the University of Pennsylvania and companies like Spark Therapeutics and BioMarin Pharmaceutical is exploring its use for conditions including hemophilia B, Duchenne muscular dystrophy, and Parkinson's disease.

Safety and immunogenicity

While generally considered safe, a primary challenge is pre-existing humoral immunity in human populations from natural exposure, which can neutralize the vector and reduce therapeutic efficacy. Additionally, capsid-specific T-cell responses can eliminate transduced cells. Strategies to overcome this include engineering capsids with altered antigenic sites, using plasmapheresis to filter neutralizing antibodies, or employing empty capsid decoys. High vector doses have also been associated with toxicities, such as hepatotoxicity observed in some trials. Rigorous monitoring by agencies like the FDA and European Medicines Agency ensures the risk-benefit profile remains favorable for these transformative treatments.

Category:Viruses Category:Gene therapy